Evidence map›Paper›PMID 38301183›Full record

Observational studyJCO global oncology2024

Clinical Utility of Stepwise Bronchoalveolar Lavage Fluid Analysis in Diagnosing and Managing Lung Infiltrates in Leukemia/Lymphoma Patients With Febrile Neutropenia.

Jayashree Thorat, Surabhi Bhat, Manju Sengar, Akshay Baheti, Sweta Bothra, Maheema Bhaskar, Sandeep Prakashnarain Tandon, Sanjay K Biswas, Gaurav V Salunke, George Karimundackal and 11 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in JCO global oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Jayashree ThoratDepartment of Medical Oncology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.
Surabhi BhatHematological Cancer Consortium, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.
Manju SengarDepartment of Medical Oncology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.ORCID 0000-0002-3509-5682
Akshay BahetiDepartment of Radio-diagnosis, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.ORCID 0000-0002-5376-6750
Sweta BothraDepartment of Radio-diagnosis, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.
Maheema BhaskarDepartment of Pulmonary Medicine, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.
Sandeep Prakashnarain TandonDepartment of Pulmonary Medicine, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.ORCID 0000-0002-9745-1312
Sanjay K BiswasDepartment of Microbiology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.
Gaurav V SalunkeDepartment of Microbiology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.ORCID 0000-0001-6841-8196
George KarimundackalDepartment of Surgical Oncology, Nanavati Hospital, Mumbai, India.
Virendra Kumar TiwariDepartment of Thoracic Surgical Oncology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.ORCID 0000-0003-1333-2285
C S PrameshDepartment of Surgical Oncology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.ORCID 0000-0002-3635-0083
Neha SharmaDepartment of Medical Oncology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.
Venkatesh KapuDepartment of Medical Oncology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.
Thomas EipeDepartment of Clinical Pharmacology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.ORCID 0000-0001-9004-1233
Bhausaheb Pandurang BagalDepartment of Medical Oncology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.ORCID 0000-0001-9754-0182
Lingaraj NayakDepartment of Medical Oncology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.ORCID 0000-0001-5239-0774
Avinash BondaDepartment of Medical Oncology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.
Amit JanuDepartment of Radio-diagnosis, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.
Alok ShettyDepartment of Medical Oncology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.ORCID 0000-0001-5423-9832
Hasmukh JainDepartment of Medical Oncology, Tata Memorial Centre, Affiliated with Homi Bhabha National University, Mumbai, India.ORCID 0000-0002-9947-7065
Homi Bhabha National Institute · INDr. Balabhai Nanavati Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFebrile neutropenia (FN) is a serious complication in hematologic malignancies, and lung infiltrates (LIs) remain a significant concern. An accurate microbiological diagnosis is crucial but difficult to establish. To address this, we analyzed the utility of a standardized method for performing bronchoalveolar lavage (BAL) along with a two-step strategy for the analysis of BAL fluid. PATIENTS AND

methodsThis prospective observational study was conducted at a tertiary cancer center from November 2018 to June 2020. Patients age 15 years and older with confirmed leukemia or lymphomas undergoing chemotherapy, with presence of FN, and LIs observed on imaging were enrolled.

resultsAmong the 122 enrolled patients, successful BAL was performed in 83.6% of cases. The study used a two-step analysis of BAL fluid, resulting in a diagnostic yield of 74.5%. Furthermore, antimicrobial therapy was modified in 63.9% of patients on the basis of BAL reports, and this population demonstrated a higher response rate (63%

conclusionOur study demonstrates that a two-step BAL fluid analysis is safe and clinically beneficial to establish an accurate microbiological diagnosis. Given the crucial impact of diagnostic delays on mortality in hematologic malignancy patients with FN, early BAL studies should be performed to enable prompt and specific diagnosis, allowing for appropriate treatment modifications.

Indexed as

Febrile NeutropeniaHematologic NeoplasmsLeukemiaLymphomaAdolescentBronchoalveolar Lavage FluidHumansLungProspective Studies

Identifiers

PMID38301183
PMCPMC10846792
OpenAlexW4391426871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.